Implications of the Landmark ISCHEMIA Trial on the Initial Management of High-Risk Patients with Stable Ischemic Heart Disease

Optimal treatment strategy for managing stable ischemic heart disease is still a topic of debate. The purpose of this review by P. Vafaei et al. (Kaiser Permanente San Francisco Medical Center, California, USA) is to discuss treatment strategies for managing stable coronary artery disease. It reviews findings based on the COURAGE trial (2007) and ISCHEMIA trial (2020).
Take-home message: For the authors, when applied to a broad population with stable CAD, evidence suggests there is no benefit to an initial invasive revascularisation strategy relative to optimal medical therapy alone